ClearPoint Neuro, Inc. (CLPT)
Automate Your Wheel Strategy on CLPT
With Tiblio's Option Bot, you can configure your own wheel strategy including CLPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLPT
- Rev/Share 1.163
- Book/Share 0.7211
- PB 16.6006
- Debt/Equity 0.172
- CurrentRatio 3.5267
- ROIC -0.8918
- MktCap 338332050.0
- FreeCF/Share -0.4235
- PFCF -28.8187
- PE -15.9563
- Debt/Assets 0.1143
- DivYield 0
- ROE -0.7809
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Read More
Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
ClearPoint Neuro: Fundamentals Continue To Strengthen
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance.
Read More
ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth.
Read More
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago.
Read More
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 fourth quarter and full year results on Wednesday, February 26th, at 4:30 p.m.
Read More
About ClearPoint Neuro, Inc. (CLPT)
- IPO Date 2012-05-22
- Website https://www.clearpointneuro.com
- Industry Medical - Devices
- CEO Mr. Joseph Michael Burnett
- Employees 115